Navigation Links
BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation
Date:2/4/2008

CAMBRIDGE, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its presentation at the BIO CEO & Investor 2008 Conference will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.millennium.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The presentation will include an overview of the Company, VELCADE(R) (bortezomib) for Injection, other product candidates and upcoming corporate events. The presentation will be delivered at 11:45 a.m. ET on Monday, February 11, 2007 from the Waldorf Astoria Hotel in New York, NY. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company's website is http://www.millennium.com.

Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com.

Contact:

Kyle Kuvalanka

(617) 761-4734


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
3. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
4. Exponent to Present at the Upcoming Sidoti & Company Investor Forum and William Blair Small-Cap Growth Stock Conference
5. Stryker to Present at Investor Conference
6. AMERIGROUP Corporation to Host Investor Day
7. Milestone Scientific to Present at the Edgewater Research Investor Conference
8. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
9. Par Pharmaceutical Provides Summary of Analyst/Investor Day
10. Sunnylife Global Retains The Blaine Group For Investor Relations, Financial Public Relations
11. SGX Pharmaceuticals to Present at the BIO InvestorForum 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: